What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.”In the company’s words, NCT07061938 on ClinicalTrials.gov
- Tested for
- IgG4 Related Disease
- Main trialPhase 1/2
- “ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)”In the company’s words, NCT07061938 on ClinicalTrials.gov
Other drugs for IgG4 Related Disease
- RilzabrutinibSanofi · Phase 3
- InebilizumabAmgen · Phase 3
- ObexelimabZenas BioPharma (USA), LLC · Phase 3
- YTS109China Immunotech (Beijing) Biotechnology Co., Ltd. · Phase 1
Coming up1
- 20 Sep 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07061938
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 20 Sep 2029 | Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease | |
| Phase 1Completed | 31 Mar 2026 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026